论文部分内容阅读
目的观察静脉应用胺碘酮治疗充血性心力衰竭(CHF)伴快速心房颤动(Af)患者的短时疗效。方法76例CHF伴快速Af患者,心功能级Ⅱ～Ⅳ级(NYHA),随机分为胺碘酮组、毛花苷组,每组38例,在常规治疗的基础上,胺碘酮组首次剂量给予胺碘酮150mg缓慢静注,随后0.5～1.0mg/min微量泵维持;毛花苷组首次剂量给予去乙酰毛花苷0.4mg或0.2mg缓慢静注,1h后无效者追加0.2mg。观察用药后临床疗效、心电图改善及不良反应。结果两组患者用药后临床疗效比较差异无统计学意义(P>0.05),胺碘酮组与毛花苷组心电图改善比较差异有统计学意义(P<0.05),两组不良反应发生率分别为13.16%和10.52%。结论静脉应用胺碘酮治疗CHF伴快速Af短时疗效显著,患者不良反应较少。
Objective To observe the short-term efficacy of intravenous amiodarone in patients with congestive heart failure (CHF) and rapid atrial fibrillation (Af). Methods Sixty-six CHF patients with fast-acting Af and NYHA were randomly divided into amiodarone group and curcumin group, with 38 patients in each group. On the basis of routine treatment, A dose of amiodarone 150mg slow intravenous injection, followed by 0.5 ~ 1.0mg / min trace pump to maintain; the first dose of sage glycosides given toostearyl 0.4mg or 0.2mg slow intravenous injection, after 1h additional invalid 0.2mg. Observed after treatment of clinical efficacy, ECG improvement and adverse reactions. Results There was no significant difference in clinical curative effect between the two groups (P> 0.05). There was significant difference between the amiodarone group and the glomerupin group (P <0.05), and the adverse reaction rates of the two groups were respectively 13.16% and 10.52% respectively. Conclusion Intravenous amiodarone treatment of CHF with fast Af short-term effect is significant, patients with less adverse reactions.